A new joint model for longitudinal and survival data with a cure fraction  by Chen, Ming-Hui et al.
Journal of Multivariate Analysis 91 (2004) 18–34
A new joint model for longitudinal and survival
data with a cure fraction
Ming-Hui Chen,a Joseph G. Ibrahim,b, and Debajyoti Sinhac
aDepartment of Statistics, University of Connecticut, Storrs, CT 06269-4120, USA
bDepartment of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill,
NC 27599-7420, USA
cDepartment of Biostatistics and Epidemiology Medical University of South Carolina, Charleston,
SC 29425, USA
Received 29 October 2003
Abstract
We develop a new joint cure rate model for longitudinal and survival data. The model
allows for multiple longitudinal markers as well as a cure structure for the survival component
based on the promotion time cure rate model, as described in Ibrahim et al. (Bayesian Survival
Analysis, Springer, New York, 2001). Several characteristics and properties of the new model
are discussed and examined. A real dataset from a melanoma clinical trial is given to
demonstrate the methodology.
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1. Introduction
Joint models for longitudinal and survival data have recently become quite
popular in cancer, AIDS, and environmental health studies where a longitudinal
biologic marker or health-related outcome such as CD4 count, immune response to
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vaccine, or quality of life in a clinical trial can be an important predictor of survival
or some other time-to-event. Often these longitudinal measures are incomplete or
may be prone to measurement error. Since such longitudinal markers (covariates)
are measured with error, the analysis becomes more complex than one that treats
these as ﬁxed covariates in a survival model. Simply including the raw longitudinal
measurements in the survival analysis leads to bias as pointed out by Prentice [21].
Therefore, methods which can model both the longitudinal and the survival
components jointly are becoming increasingly essential in such studies. For a
detailed examination of frequentist and Bayesian methods for joint models of
longitudinal and survival data, we refer the reader to Ibrahim et al. [13]. There has
been a notable literature in this area including DeGruttola et al. [7], DeGruttola and
Tu [6], Taylor et al. [24], Tsiatis et al. [25], LaValley and DeGruttola [18], Wang and
Taylor [26], Xu and Zeger [27], Song et al. [23], Brown and Ibrahim [1,2], and
Ibrahim et al. [14].
In cancer vaccine (immunotherapy) trials, which is the application considered in
this paper, vaccinations are given to patients to raise the patient’s antibody levels
against the tumor cells. In these studies, the time-to-event endpoint is often time to
disease progression or time to death. A successful vaccine activates the patient’s
immune system against future tumor growth. In this case, a patient’s antibody
production increases, indicating a possible increase in the bodies’ immune strength.
Therefore, measuring these antibodies helps the clinician to evaluate the immunity
level. However, the observed antibody titers are at best an indirect measurement of
the actual unobservable antibody level of the patient. Ibrahim et al. [14] and Brown
and Ibrahim [1,2] consider joint modeling for cancer vaccine trials in malignant
melanoma. One such trial is discussed in further detail in Section 6. In Section 6,
we carry out a survival analysis adjusting for two longitudinal immunological
measures commonly used in vaccine studies, these being the IgG and IgM antibody
titers (see Section 2). The levels of these markers are conjectured to be associated
with the clinical outcome (relapse-free survival and overall survival) and are
therefore monitored during follow-up. However, these markers are prone to
measurement error and therefore, the raw (IgG, IgM) data should not be used
as covariates in a survival analysis. We develop a joint model for these longitudinal
markers as well as the survival outcome. Details of this new model are given in
Section 3.
In many cancer vaccine trials, the prognosis for the patients under study might be
quite good and such patients may be ‘‘cured’’ after treatment and sufﬁcient follow-
up. In these situations, a plateau typically occurs in the survival curve and a survival
model with SðNÞ ¼ 0 is no longer appropriate. An alternative is to consider survival
models incorporating a cure fraction, as in Law et al. [19] and Brown and Ibrahim
[2]. In the melanoma clinical trial we examine here, a cure rate model appears
to be more appropriate than a survival model with SðNÞ ¼ 0; as demonstrated in
Fig. 1. We consider a new joint cure model for longitudinal and survival data
that is quite different than that of Law et al. [19] and Brown and Ibrahim [2]. In
Section 6, we demonstrate this new model in a melanoma cancer vaccine trial,
labeled E1694.
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2. Cancer vaccine trials in melanoma
Melanoma incidence is increasing at a rate that exceeds all solid tumors. Although
education efforts have resulted in earlier detection of melanoma, patients who have
deep primary melanoma (44 mm) or melanoma metastatic to regional draining
lymph nodes, classiﬁed as high-risk melanoma patients, continue to have high relapse
and mortality rates of 450% (see Kirkwood et al. [16]). Recently, several post-
operative (adjuvant) chemotherapies have been proposed for this class of melanoma
patients, and the one which seems to provide the most signiﬁcant impact on relapse-
free survival and survival is Interferon Alpha-2b (IFN). One of the major drawbacks
of IFN, and chemotherapies in general, is that they are highly toxic. As a result, there
has been a recent surge in research activity for ﬁnding effective vaccines for treating
malignant melanoma. These vaccines are not nearly as toxic and have much milder
side-effects, and could prove to be as efﬁcacious as other chemotherapies. Most
melanoma clinical trials use relapse-free survival (RFS) or overall survival (OS) as
the primary clinical outcome measures. A biologic marker of clinical outcome would
potentially permit these trials to be completed in a shorter time period and with a
smaller sample size. An accepted marker of clinical outcome would be one that
responds rapidly to treatment and whose response implies a beneﬁt regarding clinical
outcome.
The purpose of a vaccine therapy is that after administration of a vaccine, more
antibodies would be induced by the body and that would help eradicate the tumor
cells. Thus, to help measure the efﬁcacy of a particular vaccine and to understand the
biology of the cancer in question, it is critical to examine immunological variables
that assess the amount of antibody induction. The primary measures of antibody
response are the IgG and IgM antibody titers. These are continuous serology
measurements which assess the degree of antibody activity. In vaccine clinical trials,
it is then of importance to assess the amount of IgG and IgM antibody titers induced
after several vaccinations are given at various time points. The antibody titer
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Fig. 1. Kaplan–Meier RFS plots for E1694, where the solid (top) curve and the dashed (bottom) curve
corresponds to the IFN arm and the GMK arm, respectively.
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measurements could then serve as useful biologic markers for predicting clinical
outcome such as progression or death. From several pilot studies conducted, it has
been conjectured that the amount of antibody titers produced from certain vaccines
for cancer are associated with clinical outcome. In this paper, we formally address
this issue in the context of the cancer melanoma. A vaccine that has recently been
developed for treating melanoma is called GM2-KLH/QS-21, which we abbreviate
here by GMK. GM2 is a ganglioside expressed by most melanoma cells. From
previous pilot studies, patients with pre-existing natural antibody against GM2 or
patients who developed antibodies against GM2 as a result of immunization with
GMK, demonstrated an improved RFS compared to patients without GM2
antibodies.
It is of great interest then, in melanoma clinical trials, to characterize the
relationship between GMK induced antibody response, indirectly measured by the
IgG and IgM titers, and survival endpoints, such as RFS and OS. The IgG and IgM
titers are measured intermittently over several time periods, and they can be viewed
as independent measurements of a latent covariate process—an unobservable
antibody level of the body. The prognostic value of this unobservable covariate is of
great interest in these studies, and the covariate process itself may be of interest, as it
sheds light on the natural history of the disease.
The rest of this paper is organized as follows. In Section 3, we develop the basic
joint cure model. In Section 4, we derive the likelihoods and priors for our joint
model, and examine some of the model’s properties. In Section 5, we examine the
Conditional Predictive Ordinate (CPO) as a model assessment tool for model
comparisons. In Section 6, we present a detailed example of the melanoma clinical
trial E1694. We close the article with a brief discussion in Section 7. The
computational algorithms are given in Appendix A.
3. Joint cure model
For a clear focus and ease of exposition, we develop our model in the context of
vaccines in cancer clinical trials where we typically deal with a binary treatment
covariate xi: The proposed model, however, is quite general and can be used with
multidimensional and continuous covariates. Our model is well suited for the
situation in which one of the treatments consists of a vaccine and the other treatment
consists of a non-vaccine, such as a chemotherapy or placebo. Our model also
accommodates a vaccine in both treatment arms.
3.1. The longitudinal model
The longitudinal component of the model can be described as follows. Given that
the patient i is observed at time t; that is iARðtÞ; where RðtÞ is the risk set at time t;
let YiðtÞ denote the observed multivariate longitudinal response for subject i at
time t: We introduce the function, CiðtÞ for the ith patient, called the trajectory
function. It is typically modeled as a known parametric function of t and ai; where ai
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is the vector of unobserved patient-speciﬁc random effects. For subject i; CiðtÞ
represents the true, unobservable univariate immune response level at time t: The
name ‘‘trajectory’’ is meaningful, as CiðtÞ actually measures the patient-speciﬁc
trajectory of the unobserved immune level. We model the observed longitudinal
measurements based on CiðtÞ; and thus it is a critical component of the model for
understanding the biology of the vaccine and the disease. Now, CiðtÞ can be taken to
be a linear or quadratic trajectory in t: Thus, the trajectory functions for subject i are
of the form
CiðtÞ ¼ ai0 þ ai1t or CiðtÞ ¼ ai0 þ ai1t þ ai2t2; ð3:1Þ
where ai ¼ ðai0; ai1Þ0 or ai ¼ ðai0; ai1; ai2Þ0 are unknown patient speciﬁc parameters.
We assume that the ai’s vary within patients such that
aiBNðlðxiÞ;SðxiÞÞ; ð3:2Þ
where lðxiÞ is the mean of ai; SðxiÞ is the covariance matrix of ai; and both of these
quantities depend on the treatment covariate xi: We see that (3.1) is quite general and
results in trajectory functions with different intercepts, slopes, and curvatures for
each patient in a treatment group. To incorporate the effect of treatment xi on lðxiÞ
and SðxiÞ; we assume that
Eðaij jxi; lÞ ¼ mjxi and Varðaijjxi;SÞ ¼ xiS1 þ ð1	 xiÞS2 ð3:3Þ
for j ¼ 0; 1 for the linear trajectory, and j ¼ 0; 1; 2 for the quadratic trajectory. We
also write S ¼ ðS1;S2Þ: So, m0; m1; and m2 measure effects of the vaccine, respectively,
on the intercept, the slope, and the curvature of the patient-speciﬁc trajectory
function.
We assume that components of YiðtÞ are measurements of CiðtÞ at different scales
taken at time t: So, we take
YiðtÞ ¼ gðCiðtÞÞ þ eiðtÞ; ð3:4Þ
where g is a known function, CiðtÞ is the unobservable true immune level for subject
i: At time point t; the random measurement error, eiðtÞBNð0;S0Þ are independent of
CiðtÞ and they are also independent of eiðt0Þ for tat0: So, random measurement
errors at different time points of measurements are treated as white noise. The vector
of known functions g reﬂects the fact that each observed antibody level measures the
patients immune level against cancer in its own scale. For simplicity, we will use the
linear relationship
gjðCiðtÞÞ ¼ f0j þ f1jxit þ ai0 þ ai1t ð3:5Þ
or the quadratic relationship
gjðCiðtÞÞ ¼ f0j þ f1jxit þ f2jxit2 þ ai0 þ ai1t þ ai2t2 ð3:6Þ
for the jth component of Yi; j ¼ 1;y; m: Note that in (3.5) or (3.6), the terms
f0j þ f1jxit and f0j þ f1jxit þ f2jxit2 can be viewed as the ﬁxed components of the
trajectory function. We write
UiðtÞ ¼ ðUi1ðtÞ;y;UimðtÞÞ0 ¼ ðf01 þ f11xit;y;f0m þ f1mxitÞ0
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or
UiðtÞ ¼ ðUi1ðtÞ;y;UimðtÞÞ0
¼ ðf01 þ f11xit þ f21xit2;y;f0m þ f1mxit þ f2mxit2Þ0:
For the E1694 data, we have m ¼ 2: The IgG and IgM measurements are,
respectively, Yi1 and Yi2: Both of these antibody measurements are actually
measurements of the unobserved univariate immune level, but because IgG and IgM
correspond to two different antibodies, they have to be treated as two different scales
for measuring C (Table 1 shows a summary of the E1694 data).
3.2. The survival model
To motivate the construction of the survival function with cure, for subject
i ¼ 1;y; n; let Ni denote the number of metastatis-competent tumor cells for subject
i (in short, MCT). That is, Ni represents the number of tumor cells in subject i that
are capable of metastasizing (see Ibrahim et al. [13]). Here, the Ni’s, i ¼ 1;y; n; are
unobserved latent variables. Further, we assume that the Ni’s are independent and
each has a Poisson distribution with mean yi: Let ai be the vector of unobservable
random effects characterizing the induced immunological response of the ith patient.
As discussed in Section 3.1, we model the patient-speciﬁc random immune response
ai dependent on the treatment covariate xi: However, we assume that given ai; the
treatment xi does not inﬂuence Ni; the number of MCTs. We further assume that
yiðxi; ziÞ 
 yiðzi; b; g; aiÞ ¼ expðzi 0b þ ai 0gÞ; ð3:7Þ
where g is a vector of regression parameters corresponding to ai; and b is the vector
of regression coefﬁcients corresponding to the ﬁxed covariates zi; which includes an
intercept but does not include xi: Thus, yiðxi; ziÞ is the conditional mean of Ni given
ai: The case g ¼ 0 implies that the patient-speciﬁc immune response is not associated
with the number of MCTs in the body.
Further, let Uij denote the random time for the jth MCT to produce detectable
metastatic disease in the ith subject. Let SðtjkÞ denote the survival function of the
Uij’s, which depends on the vector of parameters k; FðtjkÞ ¼ 1	 SðtjkÞ; and f ðtjkÞ ¼
d
dt
FðtjkÞ: We assume that SðtjkÞ does not depend on xi and ai: The time to relapse of
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Table 1
Summary of E1694 data
Median IQR Frequency
Follow-up 1.44 1.64 Censored 404
Time to relapse 0.64 0.78 Relapse 263
Age 50.59 18.96
Frequency Frequency
Sex Male 428 Female 239
Treatment GMK 344 IFN 323
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cancer, Ti; can be deﬁned by Ti ¼ minfUij; 1pjpNig; and Ti ¼N with probability
1 when Ni ¼ 0: Assuming that UijjNi are independent, it follows that the conditional
survival function is given by
Sipðtjb; zi; g; ai; kÞ ¼ PðTi4tjb; zi; g; ai; kÞ ¼ exp½	fyiðzi; b; g; aiÞFðtjkÞg; ð3:8Þ
where yiðzi; b; g; aiÞ is given in (3.7). The conditional independence assumption on
the Uij ’s is well motivated by Yakovlev and Tsodikov [28].
From the survival model, we note that the basic idea in (3.1) and (3.8) is that we
model the trajectory function of a patient in a treatment group stochastically as a
function of the number of MCTs and Ni where Ni is the unobserved latent variable
that effects the survival function as well as the cure fraction. The marginal survival
function is given by
Sipðtjzi; b; g; k; xi; l;SÞ ¼E½expf	expfz0b þ ai 0ggFðtjkÞgjxi; l;S
¼Eðexp½	fVexpðz0bÞFðtjkÞgÞ; ð3:9Þ
where logðVÞ ¼ Z0ai0 þ Z1ai1 or Z0ai0 þ Z1ai1 þ Z2ai2 is a univariate normal random
variable with mean g0lðxiÞ: Note that given the parameters ðb; g; kÞ and
ðSðxiÞ; lðxiÞÞ; the expression in (3.9) can be evaluated easily using the moment
generating function of a log-normal random variable. This is a novel construction of
the trajectory function which leads to a joint model with a cure fraction.
In the model development, a necessary assumption is that the times of
measurements are not predictive of the event of cancer, that is, the times of the
scheduled measurements of the YiðtÞ’s do not affect either Ni or Uij : Our model here
characterizes the history of the three processes ðYiðtÞ;UiðtÞ;CiðtÞÞ given TiARðtÞ
and xi: Also in Table 2, we see that most of the IgG and IgM measurements within
the IFN arm are equal to zero and the medians and IQRs of the IgG and IgM
measurements at the different times points within the GMK arm are much larger
than those of the IFN arm. This is the main reason why we specify different means
and different variances for ai within the different treatments.
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Table 2
Summary of transformed IgG and IgM measures
logðIgGþ 1Þ logðIgMþ 1Þ
Treatment Week 0 4 12 52 0 4 12 52
Median 0.00 0.00 0.00 5.08 0.00 5.77 4.39 0.00
Mean 0.23 1.87 2.05 3.42 0.07 5.30 3.17 1.76
GMK IQR 0.00 5.08 5.08 5.77 0.00 1.38 5.08 5.08
Number of missing 108 90 144 185 19 84 85 222
Median 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Mean 0.04 0.08 0.42 0.00 0.03 0.07 0.09 0.12
IFN IQR 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Number of missing 46 24 67 191 17 23 76 192
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The proposed joint model has several advantages. First, the process CiðtÞ is shared
by the longitudinal components and the survival component to account for the
correlation between them. Thus, the survival component of the model is connected
to the longitudinal component of the model through g and g ¼ 0 implies that the
longitudinal and survival measures are not associated. Second, each longitudinal
component has its own treatment dependent process UijðtÞ; which is not shared with
the survival component, to account for the sole contribution of the trajectory
function to each longitudinal component in addition to the common process CiðtÞ:
Third, the proposed model does not require that all longitudinal responses be
observed at a given time point for the ith patient. This is an important feature of the
model as in the E1694 data shown in Table 2, only one of the IgG and IgM
measurements is available for many patients. Fourth, the mean trajectory functions
and the variances of ai vary with treatment. This property of the model is most
suitable for the E1694 data since we see in Table 2 that most of the longitudinal
measures in the IFN arm are zero. Finally, we mention that an equivalent
reparameterized version of the model speciﬁed by (3.4), (3.2), (3.8), and (3.7) is given
as follows:
ai ¼ ai 	 lðxiÞBNð0;SðxiÞÞ;
gjðCiðtÞÞ ¼ f0j þ m0xi þ f1jxit þ ai0 þ ai1t ð3:10Þ
for the linear trajectory,
gjðCiðtÞÞ ¼ f0j þ m0xi þ f1jxit þ f2jxit2 þ ai0 þ ai1t þ ai2t2 ð3:11Þ
for the quadratic trajectory, where fkj ¼ fkj þ mj for k ¼ 1; 2 and j ¼ 1 or j ¼ 1; 2;
and
yiðzi; b; g; aiÞ ¼ expðzi 0b þ ðai Þ0g þ lðxiÞ0gÞ: ð3:12Þ
In (3.12), lðxiÞ0g ¼ l0gxi measures the contribution of the treatment to the survival
component in the joint model. Based on the reparameterized model, there are no
extra parameters in the joint model with the linear trajectory function. However,
there is one extra mj for the quadratic trajectory model. Thus, for the quadratic
trajectory model, we can reduce the three mj’s to two mj ’s in the joint model. For the
quadratic trajectory model with the E1694 data, we implemented the joint models
with three mj’s as well as two mj’s and we have found that the model with one extra mj
in fact leads to much faster convergence of the Markov chain Monte Carlo (MCMC)
sampling. This phenomenon is analogous to the PX-EM algorithm of Liu et al.
(1998) [20] in the sense that the parameter-expanded model can improve the
convergence of MCMC sampling as in the EM algorithm. The partial explanation
for this is that with one extra mj; the model for ai is more balanced and each
component of l automatically corrects the mean of each component of ai in each
iteration of MCMC sampling.
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4. Likelihoods and priors
Let ai1;y; aimi denote the times at which the antibody measurements are taken,
and let CiðaijÞ denote the trajectory function evaluated at aij: Let the IgG and IgM
antibody titers for subject i be denoted by yil ¼ ðyi1l ;y; yimilÞ0; let yl ¼ ðy01l ;y; y0nlÞ0
for l ¼ 1; 2; respectively, and let y ¼ ðy10; y20Þ0: In addition, let x ¼ ðx1; x2;y; xnÞ0
and Z ¼ ðz01; z02;y; z0nÞ0: Further, let ti denote the event time for the ith subject,
which may be right censored and let t ¼ ðt1;y; tnÞ0 denote the vector of event times.
Let d ¼ ðd1;y; dnÞ0 denote the vector of censoring indicators, where di ¼ 1 indicates
a failure and di ¼ 0 indicates a right censored observation. Let D ¼ ðy; x; Z; t; dÞ
denote the observed data.
We consider a piecewise exponential model for FðtjkÞ: Towards this goal, we
construct a ﬁnite partition of the time axis, 0os1o?osJ ; with sJ4ti for all
i ¼ 1; 2;y; n: Thus, we have the J intervals ð0; s1; ðs1; s2;y; ðsJ	1; sJ : We thus
assume that the hazard for FðtjkÞ is equal to lj for the jth interval, j ¼ 1; 2;y; J;
leading to
FðtjkÞ ¼ 1	 exp 	ljðt 	 sj	1Þ 	
Xj	1
g¼1
lgðsg 	 sg	1Þ
( )
: ð4:1Þ
The likelihood function for the joint model involves two components. The ﬁrst
component involves the longitudinal process and is denoted by L1: The second
component involves the likelihood function of the time-to-event variable, T ; denoted
by L2: The likelihood function can thus be written as
LðhjDÞ ¼ L1ð/;S0;Cjy; xÞL2ðb; g; k; ajt; d; zÞ; ð4:2Þ
where
L1ð/;S0;CjDÞ ¼
Yn
i¼1
Y2
j¼1
Y
k:aikpti
jS0j	1=2
 exp 	1
2
ðyikj 	 gijðaikÞÞ0S	10 ðyikj 	 gijðaikÞÞ
 
and
L2ðb; g; ajt; d; zÞ ¼
Yn
i¼1
ðyif ðtijkÞÞdiexpð	yiFðtijkÞÞ;
h ¼ ð/;S0;C; b; g; k; aÞ; a ¼ ða10; a20;y; anÞ0; yi and FðtijkÞ are deﬁned by (3.7) and
(4.1), respectively, and f ðtijkÞ ¼ ddtFðtjkÞjt¼ti :
The prior speciﬁcations for S0; /; ai; l; S1; S2; b; g; and k are given as follows. We
specify the joint prior as
pðS0;/;l;S1;S2; b; g; kÞ ¼ pðS0Þpð/ÞpðlÞpðS1ÞpðS2ÞpðbÞpðgÞpðkÞ:
We take S0 to be of the form S0 ¼ Diagðs201; s202Þ; and take s201 and s202 to have
independent inverse gamma priors. For /; l; b; and g; we take normal priors with
diagonal variance-covariance matrices. The conditional prior for ajl;S1;S2 is
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speciﬁed as follows:
pðajl;S1;S2Þ
p
Yn
i¼1
jxiS1 þ ð1	 xiÞS2j	1=2

 exp 	1
2
ðai 	 lðxiÞÞ0½xiS1 þ ð1	 xiÞS2	1ðai 	 lðxiÞÞ
 
: ð4:3Þ
For S1 and S2; we assume Sk ¼ Diagðs2k0; s2k1Þ for the linear trajectory and Sk ¼
Diagðs2k0; s2k1; s2k2Þ for the quadratic trajectory, where k ¼ 1; 2: Then, we specify an
inverse gamma prior for each variance component. Finally, we take independent
gamma priors for k as follows:
pðkÞp
YJ
j¼1
lz0	1j expð	t0ljÞ;
where z0 and t0 are pre-speciﬁed hyperparameters. We notice that for the quadratic
trajectory, moderately informative priors for l; S1 and S2 are required due to the
extra parameter in the model. The detailed speciﬁcation of the priors for the E1694
data is provided in Section 6. Although the joint posterior distribution does not have
a closed form, the conditional posterior distributions are quite attractive and have
nice properties, and thus MCMC sampling is straightforward to carry out. The
technical details of the computational development are given in Appendix A.
5. Bayesian model assessment
To assess the goodness-of-ﬁt of the proposed model, we consider the Conditional
Predictive Ordinate (CPO). The CPO statistic has been widely used in the statistical
literature under various contexts (see Geisser [9]; Gelfand et al. [11]; Dey et al. [8];
Sinha and Dey [22]). The CPO statistic is particularly suitable for the proposed joint
models, since it does not require proper priors or existence of moments of the
sampling distribution. For the survival component of the joint model, the moments
of T do not exist. Thus, some other model assessment criteria, such as the L measure
proposed by Ibrahim and Laud [15], are not applicable for the proposed joint model.
Following the notation used in the previous section, the CPO statistic is deﬁned as
CPOi ¼ f ðyi1; yi2; ti; dijDð	iÞÞ ¼
Z
f ðyi1; yi2; ti; dijh; xi; ziÞpðhjDð	iÞÞ dh; ð5:1Þ
where h ¼ ðS0;/; l;S1;S2; b; g; kÞ; ðyi1; yi2Þ and ðti; diÞ denote the antibody
measurements and the RFS time with censoring indicator for the ith subject, Dð	iÞ
denotes the data with the ith subject deleted, and pðhjDð	iÞÞ is the posterior density
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of h based on the data Dð	iÞ: For the E1694 data, we have
f ðyi1; yi2; ti; dijh; xi; ziÞ
¼
Z Y2
j¼1
Y
k:aikpti
ð2pÞ	1jS0j	1=2exp 	1
2
ðyikj 	 gijðaikÞÞ0
"
 S	10 ðyikj 	 gijðaikÞÞ

 ðyif ðtijkÞÞdiexpð	yiFðtijkÞÞpðaijl;S1;S2Þdai
#
; ð5:2Þ
where pðaijl;S1;S2Þ denotes the conditional prior for ai; which is the ith term in
(4.3). Following Chen et al. [4], we obtain
CPOi ¼
Z
1
f ðyi1; yi2; ti; dijh; xi; ziÞ
pðhjDÞ dh
 	1
; ð5:3Þ
where pðhjDÞ is the posterior density of h based on the data including all subjects.
Using (5.3), a Monte Carlo method presented in Chen [4] is readily used for
computing CPOi if f ðyi1; yi2; ti; dijh; xi; ziÞ can be evaluated for each h: However,
due to the complexity of the joint model, an analytical evaluation of
f ðyi1; yi2; ti; dijh; xi; ziÞ does not appear possible. Therefore, we propose to use a
Monte Carlo method for this. Speciﬁcally, for a given value of h; which is a
realization from each iteration of MCMC sampling, we can generate a random
sample ai from (4.3), denoted by faðmÞi ; m ¼ 1; 2;y; Mg: This step is easy to
implement since the conditional prior distribution for ai is normal. Then, an estimate
of f ðyi1; yi2; ti; dijh; xi; ziÞ is given by
fˆðyi1; yi2; ti; dijh; xi; ziÞ
¼ 1
M
XM
m¼1
Y2
j¼1
Y
k:aikpti
ð2pÞ	1jS0j	1=2exp 	1
2
ðyikj 	 gðmÞij ðaikÞÞ0
"
 S	10 ðyikj 	 gðmÞij ðaikÞÞ

 ðyiðaðmÞi Þf ðtijkÞÞdiexpð	yiðaðmÞi ÞFðtijkÞÞ
#
; ð5:4Þ
where g
ðmÞ
ij ðaikÞ is deﬁned by either (3.10) or (3.11) and yiðaðmÞi Þ is deﬁned in (3.7) with
ai replaced by a
ðmÞ
i : Based on our experience, the proposed Monte Carlo estimate is
quite efﬁcient with a moderate size of M (say, MX500).
For comparing two competing models, a summary statistic called the logarithm of
the Pseudomarginal likelihood (LPML) (see Geisser and Eddy [10]; Ibrahim et al.
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[13]) can be used. The LPML is deﬁned as
LPML ¼
Xn
i¼1
logðCPOiÞ: ð5:5Þ
We choose the model with the largest LPML value. For the E1694 data, we will use
the LPML to compare the linear and quadratic trajectory models.
6. Analysis of the E1694 data
To illustrate the joint cure rate model, we examine data from an intergroup trial of
the Eastern Cooperative Oncology Group, the Southwest Oncology Group and
Cancer and Leukemia Group B. E1694 [17] was designed to determine if GMK was
superior to IFN with respect to RFS and OS, with a secondary goal to determine the
association of pre-existing and vaccine-induced IgM and IgG antibodies with RFS
and OS. IgM and IgG measures were taken at baseline, 4, 12, and 52 weeks. In this
analysis, we consider n ¼ 667 patients and use RFS as the time-to-event variable in
all analyses. For these data, the minimum RFS time was 0.0245 years and the
maximum RFS time was 4.309 years. Once a patient relapsed, they dropped out of
the study, and hence no longitudinal measures were collected after that time. Two
covariates included in the analysis are age ðz1Þ and gender ðz2Þ (z2 ¼ 0 if male and 1
if female). We also let xi ¼ 1 denote the GMK arm and xi ¼ 0 the IFN arm. Table 1
gives a detailed summary of RFS time, censoring status, covariates, and treatment.
Fig. 1 shows the Kaplan–Meier survival curve of the E1694 data. The Log-Rank test
p-value is 0.056. As noted in Section 1, Fig. 1 shows a plateau in the Kaplan–Meier
plot, indicating that a cure rate model is appropriate for these data. In all of the
analyses, the IgG and IgM measures were transformed to logarithms. Since many of
the IgG and IgM measures were 0 before transformation, we ﬁrst added a value of 1
to all IgG and IgM titer values, then took natural logarithms. Table 2 gives a
detailed summary of the ðlogðIgGþ 1Þ; logðIgMþ 1Þ) measures along with
summaries of missing values. From Table 2, we can see that most IgG and IgM
measures were 0 for the IFN arm. Fig. 2 shows the observed trajectory plots for each
patient on the GMK arm for the IgG and IgM titers. From Fig. 2, we see evidence of
a quadratic trend in the IgG trajectory with the peak IgG and IgM titers occurring at
approximately 4 weeks. The quadratic trend is much stronger in the IgM trajectory
than in the IgG trajectory. Thus, it appears that a quadratic trajectory function in
the longitudinal model may be appropriate for these data. We note here that the
(IgG, IgM) measures were nearly equal to zero at all time points for the IFN arm.
We consider analyses with the linear and quadratic trajectories. In both analyses, a
piecewise exponential model is used for FðtjkÞ: We take J ¼ 10 and the intervals
ðsj	1; sj ; j ¼ 1; 2;y; J were chosen so that at least one failure falls in each interval.
We take an improper uniform prior, i.e., pðkÞp1; for k: Nð0; 100Þ priors are speciﬁed
for the location parameters bj; Zj; fj1; fj2; and mj for j ¼ 0; 1; 2: For the scale
parameters s201 and s
2
02; we independently take s
2
0kBIGða ¼ 1; b ¼ 0:01Þ with density
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proportional to ðs20kÞ	ðaþ1Þexpð	b=s20kÞ: Similarly we take s2kjBIGða ¼ 1; b ¼ 0:1Þ
independently for k ¼ 1; 2 and j ¼ 0; 1; 2:
Table 3 shows posterior estimates of the parameters based on the linear as well as
the quadratic trajectory model. Firstly, we observe that the quadratic trajectory
model give a better ﬁt to the data than the linear trajectory model, as measured by
the LPML statistic, as well as the posterior estimates for f21 and f22; whose 95%
Highest Posterior Density (HPD) intervals do not include zero. Thus, we work with
the quadratic trajectory model in the remainder of this analysis. Secondly, we see
that the posterior estimates of Z2 and m2 do not include zero, giving further evidence
of the appropriateness of a quadratic trajectory model. The parameters that link the
longitudinal model to the survival model are the Zj’s, whose 95% HPD intervals all
do not contain zero, indicating an important association between (IgG, IgM) and
time-to-relapse. Since the (IgG, IgM) values were nearly all equal to zero for the IFN
arm, the parameters s22i; i ¼ 0; 1; 2 have posterior estimates very close to zero, and
95% HPD intervals that are tight around zero. This is not surprising since one does
not expect an immune response from a chemotherapy treatment. On the other hand,
the variance components for the GMK arm are s21i; i ¼ 0; 1; 2; whose posterior
estimates are far from zero and their 95% HPD intervals are above zero.
Sensitivity analyses for the choices of the prior hyperparameters and the
construction of the intervals ðsj	1; sj; j ¼ 1; 2;y; J was conducted, and the main
results were similar as long as the priors for l; S1 and S2 are not too ﬂat. In the
computations, 50,000 Gibbs samples were used to compute all posterior estimates
using a burn-in of 2,000 samples. In addition, M ¼ 500 in (5.4) was used, for
computing the LPML. Larger values of M were also tried, and the results were quite
stable. The convergence of the Gibbs sampler was checked using several diagnostic
procedures as recommended by Cowles and Carlin [5], and we found that the Gibbs
sampler converged before 2000 iterations. In particular, trace plots, Gelman–Rubin
statistics, and lag 10 autocorrelations were computed and all showed excellent
convergence. All HPD intervals were computed using a Monte Carlo method
proposed by Chen and Shao [3].
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Fig. 2. Trajectory plots for logðIgGþ 1Þ (left) and logðIgMþ 1Þ (right) for the GMK arm.
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7. Discussion
We have developed a new joint cure model for longitudinal and survival data. The
new model was successfully demonstrated on a melanoma dataset, in which we
observed that the (IgG, IgM) antibody titers are associated with longer time-to-
relapse. The new joint model accommodates two types of treatments in its
longitudinal component: a treatment based on a vaccine, as well as a treatment
that is not based on a vaccine (e.g., a chemotherapy or placebo). This development is
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Table 3
Posterior estimates for E1694 data
Parameter Linear trajectory Quadratic trajectory
Mean SD 95% HPD interval Mean SD 95% HPD interval
Z0 	0.815 0.245 (	1.301, 	0.343) 0.398 0.198 (0.021, 0.793)
Z1 0.173 0.046 (0.083, 0.265) 	0.326 0.108 (	0.530, 	0.106)
Z2 — — — 1.369 0.769 (0.245, 2.891)
b0 	0.479 0.122 (	0.723, 	0.242) 	0.426 0.124 (	0.672, 	0.186)
b1 0.125 0.068 (	0.012, 0.256) 0.155 0.069 (0.020, 0.287)
b2 	0.055 0.069 (	0.189, 0.080) 	0.026 0.070 (	0.164, 0.108)
s201 1.921 0.082 (1.760, 2.080) 1.919 0.078 (1.769, 2.074)
s202 3.591 0.131 (3.334, 3.847) 2.862 0.103 (2.666, 3.068)
f01 	0.163 0.042 (	0.246, 	0.081) 	0.086 0.042 (	0.169, 	0.005)
f11 	3.402 1.620 (	6.792, 	0.585) 	2.103 2.509 (	6.941, 2.614)
f21 — — — 	7.679 1.303 (	10.21, 	5.348)
f02 0.401 0.053 (0.297, 0.506) 0.162 0.049 (0.065, 0.256)
f12 	4.536 1.620 (	7.835, 	1.647) 8.119 2.518 (3.318, 12.945)
f22 — — — 	19.95 1.329 (	22.53, 	17.57)
m0 1.365 0.081 (1.209, 1.526) 0.957 0.079 (0.801, 1.120)
m1 7.877 1.668 (4.877, 11.259) 9.659 2.446 (5.180, 14.291)
m2 — — — 2.447 1.081 (0.869, 4.415)
s210 0.723 0.111 (0.508, 0.942) 0.818 0.108 (0.617, 1.042)
s211 18.303 4.480 (10.348, 27.432) 6.515 1.313 (4.052, 9.118)
s212 — — — 0.099 0.081 (0.011, 0.247)
s220 0.002 0.0003 (0.0016, 0.0028) 0.002 0.0003 (0.0016, 0.0028)
s221 0.002 0.0003 (0.0016, 0.0028) 0.002 0.0003 (0.0016, 0.0028)
s222 — — — 0.002 0.0003 (0.0016, 0.0028)
l1 0.223 0.054 (0.121, 0.330) 0.232 0.057 (0.127, 0.348)
l2 0.554 0.126 (0.325, 0.808) 0.563 0.131 (0.319, 0.822)
l3 0.585 0.129 (0.346, 0.844) 0.595 0.136 (0.346, 0.867)
l4 1.018 0.228 (0.611, 1.486) 1.026 0.234 (0.594, 1.491)
l5 0.616 0.139 (0.363, 0.900) 0.624 0.144 (0.358, 0.909)
l6 0.628 0.141 (0.367, 0.911) 0.630 0.145 (0.358, 0.918)
l7 0.866 0.202 (0.492, 1.270) 0.855 0.204 (0.476, 1.261)
l8 0.485 0.180 (0.267, 0.720) 0.470 0.117 (0.257, 0.709)
l9 0.776 0.209 (0.404, 1.206) 0.743 0.206 (0.376, 1.160)
l10 0.835 0.279 (0.340, 1.389) 0.811 0.275 (0.326, 1.357)
LPML 	7994.932 	7736.51
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novel and has yielded fruitful results. Future research with this model includes
allowing for a subject speciﬁc frailty to accommodate correlated survival times as
well as allowing over-dispersion in Ni; by taking NiBPoissonðWiyiÞ; for example,
and taking Wi to have a gamma or positive stable distribution. These extensions are
currently under investigation. A Bayesian approach was taken to ﬁt this model.
Although a frequentist analysis of this model is theoretically possible, our experience
shows that ﬁtting these complex models via MCMC is by far the most
straightforward way to proceed. Obtaining maximum likelihood estimates and
standard errors by bootstrap or other means are much more computationally
challenging and intensive compared to MCMC methods.
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Appendix A. Computational development
For the proposed joint model, we use MCMC sampling to carry out the posterior
computations. To develop an efﬁcient computational algorithm, we introduce the
latent variables N ¼ ðN1; N2;y; NnÞ0 into the likelihood function for the survival
component so that
L2ðb; g; a; N j t; d; zÞ ¼
Yn
i¼1
SðtijkÞNi	diðNif ðtijkÞÞdi y
Ni
i
Ni!
expð	yiÞ; ðA:1Þ
where SðtijkÞ ¼ 1	 FðtijkÞ and FðtijkÞ is deﬁned by (4.1). Note that in (A.1), Ni ¼
0; 1;y;N if di ¼ 0 while Ni ¼ 1; 2;y;N if di ¼ 1: It can be shown thatX
N
L2ðb; g; a; N j t; d; zÞ ¼ L2ðb; g; a j t; d; zÞ;
which is the second term on the right-hand side of (4.2). Using the collapsed
Gibbs technique, we sample from the following conditional posterior distributions
in turn:
(1) ½aj/;S0; b; g; k; l;S1;S2; D; which is log-concave, where l; S1 and S2 are deﬁned
in (4.3).
(2) ½/jS0; a; D; which is a multivariate normal distribution with mean and variance–
covariance matrix depending on the form of the trajectory function.
(3) ½S0j/; a; D; which consists of two conditionally independent inverse gamma
distributions.
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(4) ½lja;S1;S2; D is a multivariate normal distribution, and its dimension, mean,
and covariance matrix depends on the form of the trajectory.
(5) ½S1;S2ja; l; D; which is the product of 4 (or 6) independent inverse gamma
distributions depending on the linear (or quadratic) trajectory.
(6) ½bjg; k; a; D has the density
pðbjg; k; a; DÞpL2ðb; g; ajt; d; zÞpðbÞ:
Note that this conditional distribution does not depend on N and it can be
shown that pðbjg; k; a; DÞ is log-concave.
(7) ½gjb; k; a; D; which is similar to pðbjg; k; a; DÞ: Thus, the density of this
conditional distribution is also log-concave.
(8) For each latent variable,
Nijb; g; k; DBPðSðtijkÞyiÞ þ di;
where PðSðtijkÞyiÞ denotes the Poisson distribution with mean SðtijkÞyi:
(9) Given N ; the conditional posterior density for k is
pðkjN ; b; g; a; DÞp
Yn
i¼1
SðtijkÞNi	di f ðti j kÞdipðkÞ:
With independent gamma priors for the lj’s and using (4.1), it is easy to see that
½kjN ; b; g; a; D consists of J independent gamma distributions.
Thus, for (2)–(5), (8) and (9), the generation is straightforward, while for (1), (6)
and (7), we can use the adaptive rejection algorithm of Gilks and Wild [12],
since the corresponding conditional posterior densities are log-concave. We notice
that the latent variables N ¼ ðN1; N2;y; NnÞ0 are used only in (8) and (9). After
introducing the latent variables N ¼ ðN1; N2;y; NnÞ0; sampling k from its
conditional posterior distribution becomes extremely simple. Otherwise, sampling
k would be quite difﬁcult. The use of the collapsed Gibbs technique will reduce
the autocorrelation in the Markov chain induced by the latent variables
N ¼ ðN1; N2;y; NnÞ0 for the other model parameters. Thus, the combination of
these two techniques is quite effective since they lead to an easy implementation of
MCMC sampling and at the same time maintain a good mixing of the resulting
Markov chain.
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